SeekInCare's Innovative Blood Test Revolutionizes Early Cancer Detection Across Multiple Types

SeekInCare Revolutionizes Early Cancer Detection

In a significant advancement in the fight against cancer, SeekInCare® has emerged as a groundbreaking tool for early detection across various cancer types. This innovative multi-omics blood test, developed by SeekIn Inc., recently received clinical validation, as reported in the esteemed Journal of Molecular Diagnostics. With the aim of transforming how we approach cancer screening, SeekInCare combines genomic, epigenetic, and proteomic analyses to spot cancers at their infancy.

Key Features of SeekInCare

1. Comprehensive Cancer Detection
SeekInCare utilizes shallow whole-genome sequencing to analyze cell-free DNA (cfDNA) and identifies seven protein tumor markers from just an 8ml blood sample. This innovative test assesses multiple hallmarks of cancer: from copy number aberrations to fragment sizes and oncogenic viruses. By integrating advanced artificial intelligence algorithms, the test distinguishes cancer patients from non-cancer individuals effectively, while also predicting the likely origin of the tissue.

2. Robust Clinical Validation
A robust study reflected the effectiveness of SeekInCare. A retrospective analysis involving 617 cancer patients across 27 types and 580 non-cancer individuals yielded a sensitivity of 60.0% with an impressive specificity of 98.3%. As cancer stages progressed from I to IV, sensitivity rates increased substantially – from 37.7% in stage I to 78.1% in stage IV. This strong performance highlights SeekInCare's reliability in detecting various cancer types at different stages.

3. Real-World Evidence
The potential of SeekInCare was further substantiated through a prospective cohort study involving 1,203 individuals, achieving a sensitivity of 70.0% at a specificity of 95.2%. This study was monitored over a median follow-up period of 753 days, further confirming the test's effectiveness in a real-world setting.

4. Comparison with Leading Tests
SeekInCare's performance closely rivals many other multi-cancer early detection (MCED) tests currently being developed. This positions SeekInCare as a promising candidate for cancer screening at a population level, especially among high-risk groups.

Addressing Cancer Screening Needs

Despite recent strides in cancer therapies, the reality remains that a significant number of cancers are diagnosed at advanced stages when treatment outcomes are less favorable. Traditional screening often targets specific cancer types and may involve invasive procedures that discourage participation. In contrast, SeekInCare's non-invasive, blood-based approach offers a comprehensive solution for broad-spectrum cancer detection, utilizing a simple blood draw to provide valuable insights.

Dr. Mao Mao, the founder and CEO of SeekIn Inc., emphasizes the importance of this advancement, stating, "Our findings illustrate the powerful synergy of integrating multiple molecular signatures from blood to enhance the efficacy of early cancer detection. The strong performance of SeekInCare in both retrospective and prospective studies underscores its potential clinical utility as a screening tool, particularly for at-risk populations."

About SeekInCare

SeekInCare aims to detect cancer while it is still manageable, leveraging a multi-omics perspective that encompasses an overview of blood cell-free cancer signatures and clinically validated protein biomarkers. The technology employs a proprietary AI-driven algorithm designed to maximize detection accuracy across a spectrum of cancer types. SeekInCare is particularly intended for use among individuals considered at elevated risk for cancer and should be used in conjunction with approved single-cancer type screening tests.

About SeekIn Inc.

Founded in Shenzhen, China, in early 2018, SeekIn Inc. is dedicated to pioneering blood-based cancer detection technologies. The company has developed innovative solutions not only for cancer early detection but also for monitoring postoperative recurrences and evaluating treatment responses. SeekIn's contributions to the field of oncology include successful applications of their technology in veterinary settings, underscoring the versatility and potential reach of their innovations.

Through extensive collaborations with leading hospitals, SeekIn is determined to reshape the future landscape of cancer detection, aspiring to cut down cancer mortality rates significantly.

For more insights about SeekIn's pioneering technology and products, their website offers additional details: www.seekincancer.com.